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BACKGROUND AND PURPOSE
Understanding drug effects on the heart is key to safety pharmacology assessment and anti-arrhythmic therapy development.
Here our goal is to demonstrate the ability of computational models to simulate the effect of drug action on the electrical
activity of the heart, at the level of the ion-channel, cell, heart and ECG body surface potential.
EXPERIMENTAL APPROACH
We use the state-of-the-art mathematical models governing the electrical activity of the heart. A drug model is introduced
using an ion channel conductance block for the hERG and fast sodium channels, depending on the IC50 value and the drug
dose. We simulate the ECG measurements at the body surface and compare biomarkers under different drug actions.
KEY RESULTS
Introducing a 50% hERG-channel current block results in 8% prolongation of the APD90 and 6% QT interval prolongation,
hERG block does not affect the QRS interval. Introducing 50% fast sodium current block prolongs the QRS and the QT
intervals by 12% and 5% respectively, and delays activation times, whereas APD90 is not affected.
CONCLUSIONS AND IMPLICATIONS
Both potassium and sodium blocks prolong the QT interval, but the underlying mechanism is different: for potassium it is due
to APD prolongation; while for sodium it is due to a reduction of electrical wave velocity. This study shows the applicability of
in silico models for the investigation of drug effects on the heart, from the ion channel to the ECG-based biomarkers.
Abbreviations
AP(D), action potential (duration); APD90, the action potential duration at 90%; hERG, human ether-a-go-go related
gene, encoding the major IKr channel protein; ICH, International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use; IC50, the half-maximal inhibitory concentration;
IKr, rapidly activating potassium current; IKs, slowly activating potassium current; INa, fast sodium current; ICaL, L-type
calcium current; QT(c), the Q to T interval of the ECG (corrected for heart rate); Vm, transmembrane potential
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Introduction
Even though drugs are designed to bind to specific targets to
treat specific diseases, many of them exhibit multiple off-
target interactions, which can lead to drug safety problems.
Prediction of these undesirable drug-induced side effects is a
major goal for pharmaceutical companies and regulatory
agencies (Recanatini et al., 2005). The total estimate of pre-
clinical and clinical assessments for a compound that is
released to the market is at least $800 million (see Adams and
Brantner, 2006). Withdrawal of a drug after approval repre-
sents not just a safety risk to patients but also a massive loss
of investment of resources, time and money. Predicting drug
side effects in the heart as early as possible during the drug
development process is therefore a priority for safety phar-
macology (Pollard et al., 2010).
One of the most dangerous potential drug side effects is
electrophysiological cardiotoxicity (Valentin and Hammond,
2008), resulting from pro-arrhythmic abnormalities in the
electrical activity of the heart caused by the interaction of
drug molecules with cardiac ion channels. According to some
estimates, around 40% of all novel pharmaceutical com-
pounds have an effect on cardiac ion channels (Noble, 2008).
In the worst-case scenario, drug side effects can result in
sudden cardiac death caused by lethal arrhythmias such as
Torsades de Pointes (see Krikler and Curry, 1976 and De Bruin
et al., 2005).
Since arrhythmias are rarely observed in clinical trials, a
variety of both preclinical and clinical biomarkers have been
proposed to predict drug-induced pro-arrhythmic risk in
several animal models as well as humans (Corrias et al.,
2010). The QT interval in the ECG is one of the main biomar-
kers used in the assessment of cardiac safety (Recanatini et al.,
2005; Pollard et al., 2010). Quantification of drug-induced
effects on the QT interval is mandatory in the clinical human
Thorough QT trial (Gintant, 2011) before approval by regu-
latory agencies, following the Guidance for Industry report
(ICH. E14, 2005). Drugs that prolong or shorten the QT
interval in the ECG are considered to have pro-arrhythmic
consequences (Straus et al., 2005; Kowey and Malik, 2007; Lu
et al., 2008; Pugsley et al., 2008), and their development is
generally discontinued.
Preclinical assessment of cardiac compounds therefore
aims at detecting drugs that would result in QT prolongation
in the clinical Thorough QT trial. Different testing strategies
(Pugsley et al., 2008) are applied to assess drug cardiac safety,
including:
(i) ion channel binding assays (to determine the binding
affinity between the drug and cardiac ion channels);
(ii) voltage-clamp analysis of ion-channel currents (in par-
ticular the hERG potassium channel; see (Curran et al.,
1995; Vandenberg et al., 2001; Redfern et al., 2003;
Sanguinetti and Mitcheson, 2005; Hancox et al., 2008;
Gintant, 2011);
(iii) action potential recordings in isolated myocytes and
tissue (see Hondeghem et al., 2001; Valentin et al., 2004);
(iv) measurement of drug-induced changes to the QT inter-
val in small, and later large, mammals (Fossa et al.,
2002).
However, predicting drug-induced QT prolongation in
the Thorough QT trial from the results of preclinical testing
presents some unresolved issues, related to the fact that pre-
clinical assessment heavily relies on animal testing. This
implies ethical concerns, which trigger the need for the devel-
opment of novel methodologies to reduce, refine and replace
animal experimentation. Interspecies differences in drug
effects between animals and humans could also explain limi-
tations in the predictive capacity of preclinical models, as
quantified in previous studies (Valentin and Hammond,
2008).
In recent years, computational modelling and simulation
has proven to be a powerful tool for investigations of the
effect of drugs, mutations and disease on cardiac electro-
physiological activity (Clancy and Rudy, 1999; Sale et al.,
2008). The sophistication of current computational physiol-
ogy technology and its application to drug safety assessment
has attracted the interest of both regulatory agencies and
industry, as shown in recent papers (Davies et al., 2012;
Fletcher et al., 2011; Mirams et al., 2011; Valentin and
Hammond, 2008; Soubert et al., 2009; Sanchez et al., 2012).
In the present study, we describe the first computer simula-
tions of the effect of drug action on the electrophysiological
activity of the human ventricles from the ion channel to the
body surface potentials. A three-dimensional human whole-
body model with biophysically detailed representation of
electrophysiological ionic processes in the heart is developed
based on human anatomical and functional data. Computer
simulations are conducted using the human body model to
investigate the multiscale effects of potassium and sodium
blockers on ionic currents, on action potential throughout
the ventricles, on whole-ventricular activation and repolari-
zation dynamics and on body surface potentials.
Methods
In this section, we provide a description of the models,
numerical algorithms, computational software and the ana-
tomical model used to simulate the electrical propagation
from cardiac ionic currents to body surface.
Three-dimensional (3D) anatomical model of
the human body
A 3D anatomical finite-element mesh of the human body was
developed from human anatomical data1 as described in
Chapelle et al. (2009). Figure 1A presents the computational
mesh including a detailed representation of the heart and
surrounding tissues such as bones and lungs. In brief, data
were pre-processed using the 3-matic2 software in order to
obtain surface meshes, and then the meshing software Yams
(Frey, 2001) and GHS3D (George et al., 1990) to further
process the surface meshes and generate the final 3D compu-
tational meshes. The mesh contains 2 401 151 vertices and
14 336 528 tetrahedral elements. The resolution of the mesh
in the heart is 0.06 cm, close to the value of 0.05 cm reported
as sufficient to ensure numerical convergence in terms of
1http://www.3dscience.com
2http://www.materialise.com
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conduction velocity and activation times using the Chaste
software (see Niederer et al., 2011).
In order to introduce anisotropy in the myocardium, real-
istic fibre orientation was included in the model using a rule
based method (Bishop et al., 2009), as shown in Figure 1C.
Electrical model
The electrical activity throughout the ventricles and the
whole body is simulated using the bidomain equations and
the human mesh described above. In brief, the bidomain
model represents the myocardium as two domains, the intra-
cellular and extracellular domains, connected by the cell
membrane, at each mesh point (see, e.g. Tung, 1978; Sundnes
et al., 2006). The Laplace equation is used to compute extra-
cellular potentials in the human body, outside the heart. The
equations are used to calculate at each time the distribution
of transmembrane potentials at each point in the heart and
the distribution of the extracellular potential at each point of
the body.
In our model, the heart–torso interface is assumed to be a
perfect conductor, allowing for continuity of both current
and potential between the extracellular myocardial region
and the torso region. Previous studies (Lines et al., 2003a;
Potse et al., 2003; Clements et al., 2004) consider heart and
torso to be isolated; that is, the electrical current does not
flow from the heart to the torso. This approximation reduces
computational cost because it uncouples the Laplace equa-
tion in the torso from the bidomain equations in the heart,
but numerical evidence has shown that it can compromise
the accuracy of the ECG signals (see, e.g. Lines et al., 2003b;
Pullan et al., 2005; Boulakia et al., 2010). Thus, in order to
compute ECGs accurately, we consider the state-of-the-art
heart–torso fully coupled electrophysiological problem repre-
senting the cardiac electrical activity from the cell to the
human body surface. Details on the model equations can be
found in the Supporting Information Appendix S1 (section
‘Electrical Model’).
Heterogeneity in conductivities in the heart and different
parts of the body highlighted in Figure 1A was represented
in the model by considering different conductivity tensor
values. The conductivity tensor in the torso was assumed
isotropic. The torso conductivity T depends on three differ-
ent regions defined in the computational mesh: T = 0.056
S cm-1 in the skeleton (Schwan and Kay, 1957), T = 0.9 S cm-1
in the lung (Rush and Driscoll, 1969), and T = 0.76 S cm-1 in
the transverse skeletal muscle conductivity (Epstein and
Foster, 1983), for the remaining tissue. Conductivities in the
myocardium were taken from Clerc (1976).
In the absence of the Purkinje network, a time-dependent
initial stimulus was applied on the endocardium to mimic a
realistic electrical activation sequence in the heart. Propaga-
tion of the electrical excitation throughout the ventricles
occurred from apex to base following endocardial stimulation
in the left and the right ventricle. The duration of the
intra-cellular stimulus was 0.5 ms, and its strength was
100 mA cm-3.
Human ventricular action potential model
including drug action
Membrane kinetics at each human ventricular mesh point
was represented by the biophysically detailed TP06 human
ventricular action potential model (Ten Tusscher and Pan-
filov, 2006). In brief, the TP06 model includes equations for
the main ion channels, transporters and pumps involved in
the generation of the human action potential and the asso-
ciated intracellular sodium, calcium and potassium concen-
trations. Calcium dynamics in the subspace, cytoplasm and
sarcoplasmic reticulum are also represented in the model. The
Ten Tusscher and Panfilov model has been extensively used
and compared against experimental human data, showing
good performance in terms of action potential and repolari-
zation mechanisms (Romero et al., 2009). It therefore repre-
sents an adequate model to investigate drug-induced effects
on repolarization mechanisms from multiple drug/ion
channel interaction to surface body ECG. Transmural hetero-
geneity in ionic properties was also included as in previous
studies (Ten Tuscher and Panfilov, 2006). Whereas the causes
of and gradients in transmural heterogeneity are under
debate and have been reported to take many forms (Yan et al.,
2003; Glukhov et al., 2010; Keller et al., 2011; Janse et al.,
2012), here we chose to represent three layers, corresponding
to epicardial, midmyocardial and endocardial tissue, by
assigning specific properties to the transient outward current
(Ito), and the slow and rapid components of the delayed
rectifier potassium current (IKs and IKr), similar to Ten Tuss-
cher and Panfilov (2006).
The human TP06 action potential model was modified to
include the action of potassium and sodium blockers. A3http://www.inria.fr/en/
Figure 1
A. Human body mesh including detailed representation of the
cardiac ventricles as well as lung, skeleton and remaining tissue. B.
Definition of cell heterogeneity in the human cardiac ventricles
including endocardium, mid-myocardium and epicardium. C. Orien-
tation of ventricular fibres in the human ventricular model. These
meshes were generated and processed in collaboration with INRIA3
(Chapelle et al., 2009).
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single pore block model was used (similar to Brennan et al.,
2009; Mirams et al., 2011; Zemzemi et al., 2011) to model the
drug-ionic current response curve (i.e. the amount of current
block with respect to drug dose, based on the drug IC50 value
and a Hill coefficient). In this study, we simulated the effect of
blocking IKr using two concentrations equal to IC50 and 10
times IC50 values and the effect of blocking the fast Na current
INa using IC50 value and twice IC50 value. These drug doses are
in the range of the doses prescribed clinically, which are
usually less than 30 times the IC50 value (see Redfern et al.,
2003; Mirams et al., 2011). The model could be easily
extended to include drug effects on multiple ionic currents by
modifying the corresponding ionic conductances as done
here for the potassium and the sodium currents. We also
considered two different ICaL conductances to explore how
reported gender differences in ICaL (Verkerk et al., 2005;
Grandy and Howlett, 2006; Sims et al., 2008) could have a
potential impact in drug induced changed in the ECG. Simu-
lations were conducted for two values of L-type calcium
current (ICaL) conductance corresponding to its control value
in the TP06 model (male) and an increased value by 30% with
respect to control (female) (Verkerk et al., 2005).
Numerical implementation
All the simulations presented in this study were run with the
open source software package Chaste (Pitt-Francis et al.,
2009). Chaste (Cancer, Heart and Soft Tissue Environment)
provides an integrated modelling and simulation environ-
ment for a wide range of Systems Biology problems. The
software can be downloaded from http://www.cs.ox.ac.uk/
chaste. The Chaste bidomain finite element solver has been
used for a number of simulation studies (see, for instance,
Corrias et al., 2010), but this was the first time Chaste was
used to simulate the electrical activity of the heart embedded
in a human body mesh for ECG simulation.
Equations (1) to (3) (in the Supporting Information
Appendix S1) are solved by means of a semi-implicit time
discretization, where the diffusion term is treated implicitly
and the reaction term semi-implicitly (i.e. the transmem-
brane potential Vm is treated explicitly in the ODE system,
while the time derivative is approximated implicitly). For the
space discretization, a finite element method with tetrahedral
elements and piecewise linear basis functions was chosen.
The reader can refer to Pathmanathan et al. (2010) for a
detailed discussion on Chaste’s numerical methods. Chaste’s
parallelization is based on the message-passing standard
Message Passing Interface (MPI), and it uses ParMETIS to
ensure optimal domain decomposition. A shared-memory
aware MPI implementation was used to improve intra-node
communications.
Chaste uses PyCML (Cooper, 2009) to generate optimized
C++ code on the fly from any valid CellML file describing a
cardiac ionic model, like the Ten Tusscher and Panfilov (2006)
model used in this work. Chaste also includes the capability
of automatically generating realistic fibre orientation and
heterogeneities in ionic properties in anatomically based geo-
metrical models (Bernabeu et al., 2008). The simulations were
conducted on the HECToR4 supercomputer using 2048 cores
distributed on 128 nodes; each node has 32GB of memory. A
simulation of a heart beat takes 1.5 h.
Data analysis
The ECG was computed according to the standard 12-lead
ECG definition (see Malmivuo and Plonsey, 1995 for
instance). This includes the Einthoven limb leads (I, II and
III), the augmented leads (aVR, aVL, aVF) as well as the six
precordial leads (V1–V6).
The analysis of the simulation results also included the
generation of activation and repolarization maps, which
depict the time of activation and repolarization for each
point in the human ventricular mesh respectively. Local acti-
vation time for each point was computed as the time at which
the transmembrane potential reaches -30 mV. Local repolari-
zation time at each ventricular mesh point was computed as
the time at which the transmembrane potential reached 90%
of repolarization. The APD90 at each mesh point was com-
puted as the difference between the activation and the repo-
larization time. The dispersion of transmembrane potential is
computed as the difference between the maximum and the
minimum values of Vm in the heart at each time step. The
analysis is also based on the QT and QRS durations,
the Tpeak–Tend interval and the amplitude of the T wave in the
ECG.
Results
Simulation of the human ECG under
normal conditions
Figure 2 describes the simulation results using the human
heart–torso coupled model described above for control con-
ditions. Figure 2A and B show the ECG recorded in lead I and
the distribution of body potentials during the activation and
the repolarization phase, recorded at 40 and 310 ms after the
endocardial stimulation respectively. Figure 2C shows an
endocardial view of the activation maps, illustrating the
propagation of the electrical excitation from apex to base and
from endocardium to epicardium. The total activation time is
76 ms, which is the time taken by the wave to propagate to
the epicardium at the base of the ventricles. Figure 2D shows
a basal view of the repolarization map of the human ventri-
cles under control conditions. Results indicate that the
longest repolarization times of 363 ms are those of tissue in
the mid-myocardium of the ventricular base.
Figure 3 presents the ECG recorded in the 12 leads
obtained from the human body simulations under control
conditions. Results show that the magnitude, duration and
polarity of QRS and T-wave complexes in most of the leads are
within physiological ranges (see, e.g. Malmivuo and Plonsey,
1995; Aehlert, 2006). Furthermore, the QRS complex dura-
tion is 76 ms and the QRS orientation changes between V3
and V4, indicating that the activation sequence in the normal
ventricles is correctly reproduced (Aehlert, 2006).
The amplitude of the QRS in the lead II is very low. This
seems to be a left axis deviation, possibly due to the initial
activation. The QT duration in the simulated ECG under
control conditions is 365 ms, which is within the physiologi-
cal range of QT between 363 and 421 ms reported for 1 Hz4http://www.hector.ac.uk
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stimulation frequency (see Karjalainen et al., 1994; Malik
et al., 2002). Although in the precordial leads the T wave
seems to have the right amplitude, in the three limb leads (I,
II, III) and the augmented leads (aVF, aVL and aVR), the
T-wave amplitude is low.
Simulation of the effect of potassium channel
block on the ECGs
The interaction of drug action with the hERG channel is a
major concern for pharmaceutical companies as it is thought
to result in QT prolongation and increased risk of lethal
arrhythmias. Using the human torso model described above,
we simulated the effect of a potassium channel blocker on the
electrical activity of the ventricles and on the ECG, for two
drug doses equal to IC50 and 10 times IC50 concentrations. As
explained above, simulations were conducted for two differ-
ent values of the ICaL conductance, the control TP06 value and
an increased conductance by 30% from control. The simula-
tions allowed an investigation into the role of ICaL conduct-
ance in modulating the action of hERG channel block on
ventricular activity and ECG.
As expected, Figure 4 shows that hERG block results in QT
prolongation and changes in the T wave in the 12 leads of the
simulated ECG. As shown in Figure 5A for the lead I ECG, the
effects of hERG block on the ECG are dose-dependent and
result in prolongation of the QT interval from 365 ms in
control to 386 ms and 405 ms for IC50 and 10 times IC50 drug
dose, and in reduction of T-wave amplitude from 0.27 mV in
control to 0.2 mV for IC50 and 0.14 mV for 10 times IC50 drug
dose. Changes in the ECG following hERG block administra-
tion are explained by the effect of the drug on the action
potential and repolarization time maps, as shown in
Figure 5C. Although the pattern of repolarization time distri-
bution is similar for all doses (Figure 5C), the magnitude of
the repolarization times is modified (see colour bar scales in
Figure 5C), due to a prolongation of the action potential
duration at each location of the heart. This can be seen in
Figure 5B where we show the action potential traces recorded
at a specific location at the base of the ventricles for the three
drug doses considered. As shown in this figure, activation
time is not affected by drug application, but APD however is
clearly prolonged from 282 ms in control to 304 and 324 ms
for IC50 and 10 times IC50 drug dose, respectively (thus by
7.8% and 15% respectively). APD prolongation results in
delayed repolarization times and QT prolongation but by a
smaller amount (by 5.7% and 11% respectively). This differ-
Figure 2
Top: Distribution of electrical potentials in the body surface in control conditions, during the activation phase (A, 40 ms following endocardial
stimulation) and during the repolarization phase (B, 310 ms following endocardial stimulation). Lead I ECG plots in panels A and B are the
difference between potentials recorded in the left and the right arms (in the white ball locations). The colour bar provides a colour distribution
of the potential in mV. Panels C and D show an endocardial view of the activation time maps and a basal view of the repolarization time maps
in the human ventricles respectively.
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ence between the percentage of increasing the APD90 and the
QT interval shows that performing a single-cell study of the
drug effect is not enough to predict the percentage of QT
prolongation. Furthermore, Figure 5B shows that increasing
drug dose reduces the slope of the action potential during the
repolarization phase, which could also explain the decrease
in T-wave magnitude. Importantly, our simulations highlight
the lack of 1/1 ratio in the relationship between QT and T
wave and hERG block, caused by the highly nonlinear
dynamics determined by both structural and functional
factors underlying cardiac electrophysiology taken into
account in our model.
Figure 6 provides further quantification of drug-induced
changes in biomarkers extracted from the simulations includ-
ing the QT interval, the maximum repolarization time in the
ventricles, the QRS complex duration, Tpeak–Tend duration,
T-wave amplitude and the maximum dispersion of trans-
membrane potentials in the ventricles during the repolari-
zation phase. Figure 6A–C corresponds to control ICaL
simulations, whereas Figure 6D–F shows results for increased
ICaL.
As shown in Figures 4 and 5, hERG block results in the
dose-dependent prolongation of the QT interval, which is a
reflection of the drug-induced increase in repolarization
times. hERG block however does not affect the QRS interval
and the Tpeak–Tend duration (Figure 6B and E). In contrast, the
T-wave amplitude and the maximum Vm dispersion are
reduced during the repolarization phase, also in a dose-
dependent manner (Figure 6C and F); therefore, the reduc-
tion is larger for the larger applied drug dose.
As shown in Figure 6, the drug-induced changes are quali-
tatively similar for both ICaL conductance values considered
(compare top and bottom panels). However, increase in ICaL
conductance results in: (i) prolongation of QT interval dura-
tion, maximum repolarization time and Tpeak–Tend interval
duration; (ii) slight decrease in QRS duration; (iii) increase in
T-wave amplitude and in maximum Vm dispersion, as shown
in Figure 6. The changes in the ECG caused by increased ICaL
levels are due to an increase in the duration and plateau Vm
levels as shown in Figure 7.
Simulation of the effect of sodium channel
block on the ECGs
The sodium channel, also known as SCN5A-encoded Na+
channel, is the main contributor to the activation of the
myocardial cell (see Kohlhardt et al., 1972). The fast sodium
channels are responsible for the rapid depolarization of the
cell (AP phase 0), playing an important role in determining
the action potential upstroke velocity at a cell level (Salata
and Wasserstrom, 1988) as well as the propagation velocity in
tissue (Bezzina et al., 2006; Lu et al., 2010). The drugs that
mainly target the sodium channels are known as class I drugs.
They are used to treat different atrial and ventricular arrhyth-
mia like tachycardia and fibrillation, but they can increase
arrhythmic risk (see Yap and Camm, 2003).
Figure 8 illustrates the simulated first ECG-lead (A), the
action potential traces at a basal ventricular location (B) as
well as activation (C) and repolarization (D) maps for control,
IC50 and twice IC50 doses of a sodium blocker. Quantification
of biomarkers is also shown in the histograms presented in
Figure 3
Simulated standard 12-lead ECG (right) using the human torso model and the 9-lead positions (left) in normal conditions: X-axis (small square,
40 ms; big square, 200 ms), Y-axis (small square, 0.1 mV; big square, 0.5 mV) (right).
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Figure 9. Figure 9 provides further quantification for the
drug-induced changes in different biomarkers obtained from
the simulations. Figure 9A and C corresponds to control ICaL
simulations, whereas Figure 9D and F shows results for
increased ICaL. The results of the simulations presented in
Figures 8 and 9 show that sodium block results in (i) the
prolongation of QT interval, delayed activation time and
increase in QRS interval; (ii) negligible effect on the Tpeak–Tend
interval; (iii) decrease in T-wave amplitude and (iv) increase
in maximum Vm dispersion.
The simulated ECG traces show that sodium block causes
an enlargement of the QRS interval of about 18 and 30 ms for
IC50 and twice IC50 drug doses (Figures 8A and 9A). This is
caused by the delay in activation times (Figure 8C), resulting
from a decrease in conduction velocity throughout the ven-
tricles due to slow upstroke velocity of the action potential
(Figure 8B).
Even though sodium channel block does not affect the
repolarization phase of the action potential at the cell level
(see Figure 8D, showing the APD90 distribution), the T wave
in the ECG exhibits important changes in polarity and ampli-
tude (Figure 8A). The deflection of the T wave could be
explained by a change of the repolarization wave polarity
introduced by a long delay in the activation in the base of the
heart. The decrease in the magnitude of the T wave is known
to result from a reduction in the dispersion of repolarization,
which may have important anti-arrhythmic consequences
for the prevention of Torsades de Pointes in LQT2 and LQT3
models of the long-QT syndrome as mentioned in Shimizu
and Antzelevitch (1997).
The changes in the ECG biomarkers are qualitatively
similar for both ICaL values considered (Figure 9). However,
simulations show that increasing ICaL by 30% results in QT
prolongation and an increase in the T-wave amplitude for all
the considered Na block doses. These changes are explained
by the increase in plateau level and duration of the action
potential illustrated in Figure 7A. However, maximum activa-
tion times, QRS, Tpeak–Tend and maximum Vm dispersion
remained similar for both ICaL values considered and all drug
doses.
Figure 4
Effect of hERG channel block on the simulated 12-lead ECG. Body surface potentials recorded for the 12-lead ECG are shown for normal conditions
and following application of an IC50 dose of a hERG channel blocker: X-axis (small square, 40 ms; big square, 200 ms), Y-axis (small square, 0.1 mV;
big square, 0.5 mV).
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Discussion
The present study shows the first computer simulations of
drug action from the ionic currents in the ventricles to the
body surface electrocardiogram. A 3Dmultiscale human body
anatomical model is constructed to simulate the clinical ECG,
including the cardiac ventricles, lungs, bones and the sur-
rounding tissue. The anatomically based electrophysiological
model of the cardiac ventricles coupled to the whole body
includes realistic representation of the ionic membrane kinet-
ics, geometry, fibre orientation and electrophysiological het-
erogeneity in the ventricles. Computer simulations using the
3D human torso model and the efficient open source simu-
lator Chaste are conducted under physiological conditions
and following the application of sodium and potassium
blockers, for several conductance values of the L-type calcium
Figure 5
Simulated effect of hERG block on the lead I ECG(A) and time course of the action potential at a location of the base of the ventricles (B) for normal
conditions, IC50 dose and 10 times the IC50 dose. Panel A, X-axis (small square, 40 ms; big square, 200 ms), Y-axis (small square, 0.1 mV; big
square, 0.5 mV). Panel C (resp. D): left ventricle wall view of the activation (resp. repolarization) time maps for control, IC50 dose and 10 times
IC50 from (left to the right). Times are in ms.
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current. Our study shows the power of multiscale simulations
in bridging ionic, cellular, whole ventricular and body surface
levels in cardiac electrophysiology to identify the nonlinear
mechanisms underlying changes in ECG-based biomarkers
caused by drug effects.
In agreement with clinical findings, simulation results
show that the application of a potassium channel blocker
results in QT interval prolongation as well as reduction in
T-wave amplitude. As expected, QT interval prolongation is
explained by APD prolongation caused by hERG block,
whereas a decrease in T-wave amplitude correlates with a
decreased dispersion in repolarization. The sodium channel
block provokes a widening of QRS interval and QT interval
prolongation in the ECG, caused by a prolongation of total
activation time due to decreased conduction velocity, in
agreement with previous studies (Salata and Wasserstrom,
1988; Bezzina et al., 2006). Therefore, our computer simula-
tions are able to reproduce the known effects of potassium
and sodium blockers on the electrophysiological activity of
the ventricles at the ionic, cellular, whole ventricular and
ECG levels. This could be considered as a first step towards
the validation of electrophysiological model and the use of
computational tools in drug effects assessment based on the
ECG simulation. Simulations under physiological conditions
and following sodium and potassium drug block were con-
ducted for two values of the L-type calcium conductance
(normal and increased by 30%). Variability in ionic currents,
and in particular in the L-type calcium current, is thought to
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Figure 6
Histograms comparing the effect of a potassium blocker on different biomarkers for control condition IC50 dose and 10 times IC50 dose, when the
L-type calcium current level is 100% (A, B and C) and when L-type calcium current level is 130% (D, E and F). Panel A (resp. D) compares the
QT-interval and repolarization times for the three drug doses when the L-type calcium current level is 100% (resp. 130%). Panel B (resp. E)
compares the QRS duration and the Tpeak–Tend when the L-type calcium current level is 100% (resp. 130%). Panel C (resp. F) compares T-wave
amplitude and AP dispersion when the L-type calcium current level is 100% (resp. 130%).
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underlie inter-subject and gender differences in pro-
arrhythmic risk and ECG changes caused by pharmacological
interventions (Romero et al., 2009). Indeed, a large ICaL con-
ductance represents a large influx of calcium during the
action potential and therefore an increased propensity for the
development of early and delayed after-depolarizations
(Miura et al., 1993; Volders et al., 2000). Large ICaL conduct-
ance has also been suggested as one of the reasons for the
higher propensity of development of drug-induced Torsades
de Pointes in women than in men (Abi-Gerges et al., 2004;
Verkerk et al., 2005). Our simulations show that increased ICaL
conductance results in slight decrease in QRS, prolongation
of QT interval and increase in T-wave amplitude. At the
cellular level, our simulations show that the changes are
caused by increased conduction velocity due to a faster AP
upstroke velocity and an increase in duration and amplitude
of the plateau phase of the action potential.
Our study highlights the importance of 3D human body
simulations for the prediction of the magnitude of drug-
induced changes in the QT interval. In fact, when introduc-
ing a 50% potassium block, the percentage of APD90
prolongation was 7.8%, whereas the percentage of the QT
interval prolongation was 5.7%, highlighting the nonlinear
relationship between current block and changes in the ECG
biomarkers. The difference between APD and QT prolonga-
tion is even larger for sodium channel blockers: the APD is
not affected following application of IC50 or twice IC50 sodium
block drug doses whereas the QT was prolonged by 5% for
IC50 sodium block value and by 8.2% for twice the IC50 value.
This highlights the need to consider the wide spatio-temporal
dimensions required for the assessment of drug action on the
heart and therefore the importance of using 3D human body
models to predict drug effects on the ECG.
Previous studies have investigated the ionic mechanisms
underlying changes in the ECG caused by mutations and
diseased conditions. Most of the studies were conducted
using the simulation of unipolar pseudo-ECGs using 1D or
3D anatomically based models (see, e.g. Gima and Rudy,
2002; Corrias et al., 2010; Pueyo et al., 2010; Dux-Santoy
et al., 2011). ECG simulations have also been performed using
3D heart models embedded in a torso (Lines et al., 2003b;
Chapelle et al., 2009; Potse et al., 2009; Zemzemi, 2009; Bou-
lakia et al., 2010; Keller et al., 2011; Zemzemi et al., 2011). The
studies have shown the importance of torso effects in the
simulation of the ECG. But they often included simplified or
non-human ionic models or the obtained results are not in
physiological ranges. The present study is however the first
one to show the effect of drug action on the ECG using a
biophysically detailed model of the cardiac ventricles embed-
ded in a human torso model.
In our study, drug action at the ion channel level was
simulated using a single pore block model, as in previous
studies (Brennan et al., 2009; Davies et al., 2012; Mirams
et al., 2011). Although more sophisticated models of drug
action have been developed (Clancy and Rudy, 2001; Moreno
et al., 2011; Saiz et al., 2011), the single pore block model
successfully reproduced the drug-induced decrease in con-
ductance required. More sophisticated models of drug ion
channel interaction, including multichannel effects, may be
needed to simulate frequency-dependent effects, which were
outside the scope of the study. Our approach also has the
important advantage of using the output of high throughput
ion channel assays, which is crucial in using the 3Dmodel for
preclinical drug safety testing in the pharmaceutical industry.
Simulations of specific ion channel blockers acting on the
potassium or the sodium channels were considered, in order
Figure 7
Simulation of the effect of L-type calcium current level under potassium ion channel block. (A) Action potential trace when the potassium channel
is half blocked and the L-type calcium level at 100% (respectively 130%). (B) Lead I ECG when the potassium channel is half blocked and 100%
(130%, respectively) of L-type calcium level. X-axis (small square, 40 ms; big square, 200 ms), Y-axis (small square, 0.1 mV; big square, 0.5 mV).
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to evaluate the ability of our model to reproduce known
effects. However, simulations using our model could be con-
ducted for drugs acting simultaneously on multiple channels,
using the known IC50 values for each of the channels (similar
to the studies by Davies et al., 2012; Mirams et al., 2011).
Examples of such drugs include, e.g., Pimozide, which is a
class II drug with IC50 values for sodium and hERG channels
of 54 and 20 nM respectively (see Redfern et al., 2003; Mirams
et al., 2011). This drug and other antipsychotic drugs increase
the arrhythmic risk (Mackin, 2008). Another example is Qui-
nidine, a class I drug, used to treat atrial and ventricular
fibrillation, but with pro-arrhythmic potential (Yang and
Roden, 1996). Quinidine has been shown to block compo-
nents of the sodium current, as well as the calcium and
potassium, with hERG IC50 value 50 times lower than its
sodium IC50 (Redfern et al., 2003; Mirams et al., 2011).
Figure 8
Simulated effect of sodium channel block on the body surface ECG (A), the action potential (B), activation maps (C, left ventricle wall view) and
APD90 maps (D, basal view) for normal conditions, IC50 dose and 10 times the IC50 dose. Times are in ms. (A) X-axis (small square, 40 ms; big
square, 200 ms), Y-axis (small square, 0.1 mV; big square, 0.5 mV).
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In addition to the simulation of multi-channel drug
effects, our tool could also be used to predict multi-drug
action on the ventricles, as the risk of toxicity is higher when
using multiple drugs (Thummel and Wilkinson, 1998). Our
study shows that modelling and simulating multiple drug
administration could be addressed for suspect combination of
drugs.
In general, the simulated ECGs are promising, since the
global ECG features could be clearly seen in the simulated
signals. Nevertheless, there are many details to improve in
order to reproduce an accurate representation of the ECGs: In
particular, the QRS complex and the T-wave amplitude in the
limb and augmented leads should be improved. As concerns
the T-wave amplitude, the cell heterogeneity is a key of the
problem. There is still a debate between the fact the trans-
mural and/or apico-basal heterogeneity is modulating the
T-wave polarity and amplitude. In this work, we made the
choice to use only transmural heterogeneity. This seems to
not be enough in order to generate a sufficiently physiologi-
cal T wave.
Conclusions and perspectives
In this paper, we presented a computational simulation
showing the effect of specific drug doses on the ECG meas-
ured on the thorax surface. A combination of state-of-the-art
modelling and simulation tools and methodologies are used
in this work, which include a finite element mesh of the
human body, a biophysically detailed human bidomain
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Figure 9
Histograms comparing the effect of a sodium blocker on the biomarkers for control condition IC50 dose and two times IC50dose, when the L-type
calcium current level is 100% (A, B and C) and when L-type calcium current level is 130% (D, E and F). Panel A (resp. D) compares the QT-interval
and activation time for the three drug doses when the L-type calcium current level is 100% (resp. 130%). Panel B (resp. E) compares the QRS
duration and the Tpeak–Tend when the L-type calcium current level is 100% (resp. 130%). Panel C (resp. F) compares T-wave amplitude and AP
dispersion when the L-type calcium current level is 100% (resp. 130%).
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model of cardiac electrophysiological activity, a model of
drug/ion channel interactions and an efficient open source
software package.
Simulation results are presented showing how increasing
ion channel block (or increasing the drug dose) alters the
action potential, ventricular activation and repolarization
and the ECG. Potassium current (or hERG) block results in
prolongation of the QT interval due to APD prolongation,
which has been related to increased risk of Torsades de
Pointes. Block of the fast sodium current causes prolongation
of the QRS interval, a known cardiac risk marker, especially
for class 1C anti-arrhythmic drugs. These results are in
accordance with the clinical findings on the effect of sodium
and potassium ion channel blockers on the electrophysiology
of the heart, and in particular on their effect on the QT
interval of the ECG. We also assessed the effect of increasing
the L-type calcium in the modulation of drug effects on the
ECG.
We consider that the ECG simulator could be used as a
tool for the prediction of drug effects on the QT interval and
other ECG-based biomarkers for drug safety testing. It could
also be used for insight into and more understanding of the
drug mechanism at the organ level resulting from the
complex interplay between cardiac structure and nonlinear
membrane kinetics.
We believe that assessing the effect of single channel
block on the electrical activity of the heart from the cell level
to the ECG level is an important step before assessing multi-
ple channel effects. This allows distinguishing each of the
possible channel block effects on the APD and ECG. In future
studies, we will consider multichannel drug effects by using
the different IC50 values of the drug with respect to their
corresponding ion channels as obtained from ion channel
assays.
The models and simulations presented here constitute a
significant step forward towards realistic simulation of drug-
induced effects on the ECG.
Although the TP06 cell model provides a description of
calcium handling, the formulation is still a simplification and
cannot describe all details of calcium dynamics. Future work
will aim at overcoming some of the limitations of our current
model by, for example, including a physiological model rep-
resenting the physiological details of the calcium dynamic,
the representation of important cardiac structures such as the
specialized conduction system as previously done in (Bordas
et al., 2011) for rabbit, as well as a more systematic investiga-
tion on the role of electrophysiological heterogeneities in
determining drug effects on the heart. These state-of-the-art
methodologies could be a useful tool in the assessment of
drug cardiotoxicity and can also be extended to the investi-
gation of the effect of mutations or disease on the ECG.
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